Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CCR3 | P51677 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24854192 | 0.90 | OPRL1 (0.54) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL62966 | 0.83 | OPRM1 (0.65) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| Hydrochloric Acid SCHEMBL1147552 | 0.82 | OPRM1 (0.63) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL28548988 | 0.80 | OPRL1 (0.71) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL17714554 | 0.78 | OPRM1 (0.58) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL15325219 | 0.78 | OPRM1 (0.57) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL8804780 | 0.77 | OPRL1 (0.67) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL653329 | 0.77 | OPRL1 (0.67) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL4460491 | 0.76 | OPRL1 (0.52) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL7406058 | 0.76 | OPRL1 (0.65) | OPRL1POLBCYP3A4HSD17B10CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3097095-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | AbbVie Inc. (US) | 2016-11-30 | — | — | EP | claimed |
| WO-2015112754-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2015-07-30 | — | — | WO | claimed |
| EP-3097095-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | AbbVie Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| WO-2015112754-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| CN-100497346-C | Chemokine CCR5 receptor modulators | ROCHE PALO ALTO LLC (CH) | 2009-06-10 | — | — | CN | disclosed |
| US-7538122-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080139544-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-06-12 | — | — | US | disclosed |
| US-7332500-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-02-19 | — | — | US | disclosed |
| CN-1918171-A | Chemokine ccr5 receptor modulators | ROCHE PALO ALTO LLC (CH) | 2007-02-21 | — | — | CN | disclosed |
| EP-1716156-A2 | CHEMOKINE CCR5 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005075484-A2 | CHEMOKINE CCR5 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-18 | — | — | WO | disclosed |
| EP-0414422-B1 | 2-Oxo-1-oxa-8-azaspiro [4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof | RICHTER GEDEON VEGYESZET (HU) | 1994-04-06 | — | — | EP | disclosed |
| EP-0412820-B1 | 2-Oxo-1-oxa-8-azaspiro[4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof | RICHTER GEDEON VEGYESZET (HU) | 1994-03-02 | — | — | EP | disclosed |
| US-5157038-A | Antidepressants; tranquilizers; treatment of schizophrenia and epilepsy; antilepmic agents | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1992-10-20 | — | — | US | disclosed |
| EP-0414421-A2 | 1-Oxa-2-oxo-8-azaspiro[4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1991-02-27 | — | — | EP | disclosed |
| EP-0414422-A2 | 2-Oxo-1-oxa-8-azaspiro [4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1991-02-27 | — | — | EP | disclosed |
| EP-0413516-A2 | 4-Methylene-1-oxa-2-oxo-8-azaspiro[4,5]decane derivatives, pharmaceutical compositions containing them and processes for preparing them | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1991-02-20 | — | — | EP | disclosed |
| CN-1049348-A | New 2-oxo-1-oxa--8-azaspiro [4,5] decane derivative contains their pharmaceutical composition and preparation method thereof | RICHTER GEDEON VEGYESZET (HU) | 1991-02-20 | — | — | CN | disclosed |
| EP-0412821-A2 | 1-oxa-2-oxo-3,8-diazaspiro[4,5]decane derivatives, pharmaceutical compositions containing them and processes for preparing them | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1991-02-13 | — | — | EP | disclosed |
| EP-0412820-A2 | 2-Oxo-1-oxa-8-azaspiro[4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139544-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | OPRL1 53/4885POLB 812/4885CYP3A4 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.